# PART VI: COMMUNICABLE DISEASES
## Quick Revision Manual for Community Medicine (MBBS)

---

## CHAPTER 17: PRINCIPLES OF COMMUNICABLE DISEASE CONTROL

### I. CHAIN OF INFECTION

#### Agent (Infectious Microorganisms)
- **Bacteria**: Single-celled microorganisms (e.g., *Streptococcus, Mycobacterium tuberculosis*)
- **Viruses**: Obligate intracellular parasites (e.g., HIV, influenza virus)
- **Fungi**: Eukaryotic organisms (e.g., *Candida, Aspergillus*)
- **Parites**: Single/multi-celled organisms (e.g., *Plasmodium, helminths*)
- **Prions**: Proteinaceous infectious particles (e.g., Creutzfeldt-Jakob disease)

#### Host Factors
- **Natural resistance**: Age, sex, race, genetic factors
- **Acquired immunity**: Active (previous infection/vaccination) vs Passive (maternal antibodies, IgG)
- **Nutritional status**: Protein-energy malnutrition impairs immunity
- **Endocrine factors**: Diabetes, pregnancy increase susceptibility
- **Immunosuppression**: HIV, chemotherapy, steroids

#### Environment
- **Physical**: Temperature, humidity, overcrowding
- **Biological**: Vectors, intermediate hosts, reservoirs
- **Social**: Economic status, education, healthcare access
- **Seasonal**: Disease patterns vary with seasons

### II. MODES OF TRANSMISSION

#### 1. Direct Transmission
- **Person-to-person**: Direct contact (skin-to-skin), droplet infection
- **Mother-to-child**: Transplacental, perinatal, breastfeeding

#### 2. Indirect Transmission
- **Vehicle-borne**: Contaminated food, water, air, blood products
- **Vector-borne**: Biological (mosquitoes, ticks) or mechanical (flies, cockroaches)
- **Fomite transmission**: Inanimate objects (door handles, needles)
- **Airborne**: Aerosolized particles (<5 microns) remain suspended

### III. HOST-PARASITE RELATIONSHIPS

#### Symbiosis Types
- **Commensalism**: One benefits, other unaffected
- **Mutualism**: Both benefit
- **Parasitism**: One benefits, other harmed

#### Disease Spectrum
- **Subclinical infection**: No symptoms but pathogen present
- **Clinical infection**: Symptoms present
- **Carrier state**: Infectious without symptoms
- **Latent infection**: Dormant state (e.g., herpes, TB)

### IV. EPIDEMIOLOGICAL PATTERNS

#### Disease Distribution
- **Endemic**: Constant presence in community
- **Epidemic**: Sudden increase above normal
- **Pandemic**: Worldwide epidemic
- **Sporadic**: Irregular, occasional cases

#### Epidemic Patterns
- **Common-source epidemic**: Single exposure (point-source)
- **Propagated epidemic**: Person-to-person transmission
- **Mixed epidemic**: Both common-source and propagated

### V. PREVENTION STRATEGIES

#### Primary Prevention
- **Health promotion**: Education, lifestyle modification
- **Specific protection**: Vaccination, chemoprophylaxis, vector control

#### Secondary Prevention
- **Early diagnosis**: Screening programs, active surveillance
- **Prompt treatment**: Antimicrobial therapy, isolation

#### Tertiary Prevention
- **Rehabilitation**: Disability prevention, reconstructive surgery
- **Sequelae management**: Chronic complications, follow-up care

### VI. CONTROL MEASURES

#### International Measures
- **International Health Regulations (IHR 2005)**
- **WHO surveillance systems**
- **Cross-border coordination**

#### National Measures
- **National Disease Control Programs**
- **Epidemic investigation protocols**
- **Health infrastructure development**

#### Local Measures
- **Case surveillance and reporting**
- **Contact tracing and management**
- **Environmental sanitation**

### VII. QUARANTINE VS ISOLATION

| Aspect | Quarantine | Isolation |
|--------|------------|-----------|
| **Definition** | Restriction of well-exposed persons | Separation of infected persons |
| **Duration** | Incubation period of disease | Period of communicability |
| **Purpose** | Prevent spread from exposed individuals | Prevent spread from infected individuals |
| **Legal authority** | Public Health Act | Hospitals/Health authorities |

**Memory Aid**: Q for Quarantine (ex**Q**uired exposed), I for Isolation (Infected persons)

---

## CHAPTER 18: RESPIRATORY INFECTIONS

### I. TUBERCULOSIS

#### Epidemiological Triangle
- **Agent**: *Mycobacterium tuberculosis* (acid-fast bacillus)
- **Host**: Adults 20-40 years, HIV-positive, malnourished, diabetic
- **Environment**: Overcrowding, poor ventilation, urban slums

#### Clinical Features
- **Pulmonary TB**: Cough >2 weeks, hemoptysis, chest pain, fever, weight loss
- **Extrapulmonary**: Lymphadenitis, meningitis, bone, genitourinary
- **Tuberculin test**: Induration >10mm (BCG vaccinated >15mm)
- **Sputum examination**: Ziehl-Neelsen stain, GeneXpert MTB/RIF

#### Treatment Protocols
**First-line drugs**: 2HRZE/4HR
- **Intensive phase**: 2 months (H+R+Z+E)
- **Continuation phase**: 4 months (H+R)
- **DOT (Directly Observed Treatment)**: Essential component

**Second-line drugs**: Fluoroquinolones, aminoglycosides, ethionamide
- **Drug-resistant TB**: MDR-TB (resistant to H+R), XDR-TB

#### National TB Control Programme (NTCP)
**Objectives**: Achieve 90% case detection, 90% treatment success
**Components**: 
- DOTS implementation
- ACSM (Advocacy, Communication, Social Mobilization)
- TB-HIV collaboration
- Drug-resistant TB management

**Key Strategies**:
- Nikshay portal for surveillance
- Private sector engagement
- Community DOT providers

#### Prevention & Control
- **BCG vaccination**: Birth dose, prevents disseminated TB
- **Infection control**: N95 masks, UV lights, natural ventilation
- **Contact screening**: Household and close contacts
- **Chemoprophylaxis**: INH for latent TB infection

### II. PNEUMONIA

#### Community-Acquired Pneumonia (CAP)
- **Common pathogens**: *S. pneumoniae, H. influenzae, atypicals*
- **Risk factors**: Age >65, COPD, alcoholism, immunosuppression
- **Clinical**: Fever, cough, pleuritic chest pain, consolidation
- **Management**: Empirical antibiotics based on severity (CURB-65 score)

#### Nosocomial Pneumonia
- **Hospital-acquired pneumonia (HAP)**: >48 hours after admission
- **Ventilator-associated pneumonia (VAP)**: >48 hours post-intubation
- **Common pathogens**: *Pseudomonas, MRSA, Enterobacter*
- **Prevention**: HOB elevation, oral care, minimize ventilation duration

### III. INFLUENZA

#### Seasonal Influenza
- **Types**: Influenza A (H1N1, H3N2), Influenza B, Influenza C
- **Transmission**: Respiratory droplets, contact, airborne
- **Clinical**: Sudden onset fever, myalgia, respiratory symptoms
- **Prevention**: Annual vaccination (trivalent/quadrivalent)

#### Pandemic Influenza
- **H1N1 (2009)**: First pandemic of 21st century
- **WHO Pandemic Phases**: 1-6 (inter-pandemic to post-pandemic)
- **Characteristics**: Novel strain, global spread, high mortality

#### Avian Influenza (H5N1)
- **Source**: Poultry, wild birds
- **Human infection**: Direct contact with infected birds
- **High pathogenicity**: 60% case fatality rate

### IV. MEASLES, MUMPS, RUBELLA (MMR)

#### Measles (Rubeola)
- **Agent**: Measles virus (Paramyxovirus)
- **Transmission**: Respiratory droplets, highly contagious (R0=15-18)
- **Clinical**: Koplik's spots, maculopapular rash, fever, conjunctivitis
- **Complications**: Pneumonia, encephalitis, SSPE
- **Prevention**: MMR vaccine (9 months, 15-18 months)

#### Mumps
- **Agent**: Mumps virus (Paramyxovirus)
- **Clinical**: Parotitis, orchitis (post-pubertal males), meningitis
- **Prevention**: MMR vaccine, isolation for 5 days

#### Rubella (German Measles)
- **Agent**: Rubella virus (Togavirus)
- **Congenital rubella syndrome**: Cataracts, deafness, heart defects
- **Prevention**: MMR vaccine, avoid contact with pregnant women

### V. COVID-19

#### Epidemiological Triangle
- **Agent**: SARS-CoV-2 (Coronaviridae)
- **Host**: All age groups, higher risk in elderly, comorbidities
- **Environment**: Closed spaces, gatherings, international travel

#### Clinical Features
- **Asymptomatic**: 40-45% cases
- **Mild**: Fever, cough, fatigue, loss of taste/smell
- **Severe**: Dyspnea, bilateral pneumonia, ARDS
- **Complications**: Thrombosis, multisystem inflammatory syndrome

#### Diagnostic Tests
- **RT-PCR**: Gold standard for detection
- **Rapid antigen test**: Point-of-care testing
- **Antibody tests**: Seroprevalence studies
- **CT chest**: Ground-glass opacities

#### Prevention & Control
- **Vaccines**: Pfizer, Moderna, AstraZeneca, Bharat Biotech
- **Non-pharmaceutical interventions**: Masks, distancing, hand hygiene
- **Quarantine protocols**: 14 days for contacts
- **Travel restrictions**: International and domestic

#### National COVID-19 Response
- **Co-WIN portal**: Vaccination registration
- **Testing strategy**: Surveillance and contact tracing
- **Treatment protocols**: Remdesivir, steroids, oxygen support
- **Emergency measures**: Lockdowns, movement restrictions

---

## CHAPTER 19: INTESTINAL INFECTIONS

### I. CHOLERA

#### Epidemiological Triangle
- **Agent**: *Vibrio cholerae* (O1, O139)
- **Host**: Children and adults, gastric acidity protective
- **Environment**: Contaminated water, poor sanitation, overcrowding

#### Clinical Features
- **Incubation**: 2 hours to 5 days
- **Rice-water stools**: Characteristic appearance
- **Profuse diarrhea**: Up to 1L/hour
- **Dehydration**: Rapid fluid loss, hypokalemia
- **Complications**: Renal failure, shock

#### Diagnosis
- **Stool microscopy**: Motile vibrios (hanging drop test)
- **Culture**: TCBS agar (yellow colonies)
- **Rapid diagnostic tests**: Immunochromatography
- **Rehydration status**: Assessment of dehydration

#### Treatment
- **ORS (Oral Rehydration Solution)**: WHO formulation
- **IV fluids**: Ringer's lactate for severe dehydration
- **Antibiotics**: Doxycycline, azithromycin (reduce duration)
- **Zinc supplementation**: Children <5 years

#### Prevention & Control
- **Safe water**: Boiling, chlorination, filtration
- **Sanitation**: Proper sewage disposal, hand washing
- **Food safety**: Cooking practices, hygiene
- **Surveillance**: Active case finding, laboratory confirmation

### II. TYPHOID FEVER (ENTERIC FEVER)

#### Epidemiological Triangle
- **Agent**: *Salmonella typhi* (typhoid), *S. paratyphi* (paratyphoid)
- **Host**: School-age children, young adults
- **Environment**: Poor sanitation, contaminated food/water

#### Clinical Features
- **Stepladder fever**: Gradually increasing temperature
- **Rose spots**: Truncal maculopapular rash (2nd week)
- **Relative bradycardia**: Disproportionate to fever
- **Hepatosplenomegaly**: Enlarged liver and spleen
- **Complications**: Intestinal hemorrhage, perforation

#### Diagnosis
- **Blood culture**: Gold standard (1st week)
- **Bone marrow culture**: Highest sensitivity
- **Widal test**: Rising antibody titers (O, H antigens)
- **Typhidot**: Rapid diagnostic test
- **Stool culture**: Late in illness

#### Treatment
- **First-line**: Ceftriaxone, cefixime
- **Alternatives**: Azithromycin, fluoroquinolones
- **Supportive**: Fluids, antipyretics, nutrition
- **Carrier state**: Cholecystectomy if persistent

#### Prevention & Control
- **Typhoid vaccine**: Vi polysaccharide (injectable), Ty21a (oral)
- **Sanitation improvement**: Safe water, proper disposal
- **Food safety**: Avoid raw foods, street vendors
- **Surveillance**: Case investigation, contact tracing

### III. FOOD POISONING

#### Bacterial Food Poisoning

**Staphylococcus aureus**
- **Source**: Food handlers, dairy products
- **Toxin**: Preformed enterotoxin
- **Rapid onset**: 2-6 hours
- **Symptoms**: Vomiting, diarrhea, abdominal pain

**Clostridium perfringens**
- **Source**: Meat, poultry, legumes
- **Toxin**: Enterotoxin produced in intestine
- **8-16 hours incubation
- **Profuse diarrhea, minimal vomiting

**Bacillus cereus**
- **Source**: Rice, pasta, cereals
- **Two syndromes**: Emetic (rice), diarrheal (meat)
- **Rapid onset: 1-6 hours

**Salmonella spp.**
- **Source**: Eggs, poultry, milk
- **Symptoms**: Diarrhea, fever, abdominal pain
- **Duration**: 2-7 days

#### Viral Food Poisoning
- **Norovirus**: Most common cause
- **Rotavirus**: Children <5 years
- **Hepatitis A**: Contaminated shellfish

#### Prevention
- **Temperature control**: Cooking, refrigeration
- **Hygiene**: Hand washing, clean utensils
- **Food storage**: Proper temperature maintenance
- **Source control**: Inspection, quality assurance

### IV. AMOEBIASIS AND GIARDIASIS

#### Amoebiasis
- **Agent**: *Entamoeba histolytica*
- **Transmission**: Fecal-oral route, contaminated water
- **Clinical**: Amoebic dysentery, liver abscess
- **Diagnosis**: Stool microscopy (cysts/trophozoites), antigen detection
- **Treatment**: Metronidazole, luminal amebicides

#### Giardiasis
- **Agent**: *Giardia lamblia*
- **Transmission**: Contaminated water, person-to-person
- **Clinical**: Chronic diarrhea, malabsorption, bloating
- **Diagnosis**: Stool microscopy, antigen tests
- **Treatment**: Metronidazole, tinidazole

### V. VIRAL HEPATITIS A & E

#### Hepatitis A
- **Agent**: Hepatitis A virus (Picornavirus)
- **Transmission**: Fecal-oral, contaminated food/water
- **Clinical**: Acute viral hepatitis, self-limiting
- **Prevention**: Inactivated vaccine, immunoglobulin
- **No chronic carrier state

#### Hepatitis E
- **Agent**: Hepatitis E virus (Hepevirus)
- **Transmission**: Fecal-oral, water-borne outbreaks
- **Clinical**: Similar to Hepatitis A
- **Special concern**: Pregnancy (high mortality)
- **Prevention**: Improved sanitation, vaccine (limited availability)

### VI. POLIOMYELITIS

#### Epidemiological Triangle
- **Agent**: Poliovirus (Enterovirus, serotypes 1, 2, 3)
- **Host**: Children <5 years, unvaccinated individuals
- **Environment**: Poor sanitation, overcrowding

#### Clinical Features
- **Majority (90%)**: Asymptomatic infection
- **Minor illness**: Fever, malaise, headache, sore throat
- **Paralytic polio**: Acute flaccid paralysis, asymmetric
- **Bulbar polio**: Respiratory muscle involvement

#### Diagnosis
- **Virus isolation**: Stool samples, throat swab
- **RT-PCR**: Rapid detection
- **Serology**: Antibody detection

#### Prevention & Control
- **OPV (Oral Polio Vaccine)**: Live attenuated, provides intestinal immunity
- **IPV (Inactivated Polio Vaccine)**: Injectable, safe for immunocompromised
- **Pulse Polio Immunization**: National campaigns
- **Surveillance**: AFP (Acute Flaccid Paralysis) monitoring

---

## CHAPTER 20: VECTOR-BORNE DISEASES

### I. MALARIA

#### Epidemiological Triangle
- **Agent**: *Plasmodium* species (*falciparum*, *vivax*, *ovale*, *malariae*, *knowlesi*)
- **Host**: Humans, varying susceptibility by age/genetics
- **Environment**: Tropical/subtropical, breeding sites, climate

#### Transmission
- **Vector**: *Anopheles* mosquitoes (female)
- **Artificial**: Blood transfusion, needle sharing
- **Congenital**: Mother to fetus (rare)
- **Geographic distribution**: Species vary by region

#### Clinical Features
**Uncomplicated Malaria**:
- Periodic fever (quotidian, tertian, quartan)
- Headache, myalgia, malaise
- Splenomegaly, hepatomegaly

**Severe *P. falciparum***:
- Cerebral malaria: Altered consciousness, seizures
- Severe anemia: Hb <5 g/dL
- Renal failure: Acute tubular necrosis
- Pulmonary edema: Respiratory distress
- Hypoglycemia:Especially in pregnancy

#### Diagnosis
- **Microscopy**: Gold standard (thick/thin films)
- **RDT**: Rapid diagnostic tests (HRP-2, pLDH)
- **Molecular**: PCR (reference laboratories)
- **QBC**: Quantitative buffy coat

#### Treatment Protocols
**Uncomplicated *P. falciparum***:
- ACT (Artemisinin-based Combination Therapy)
- AL (Artemether-lumefantrine)
- AS+SP (Artesunate-sulfadoxine-pyrimethamine)

**Severe Malaria**:
- IV artesunate (first choice)
- Alternative: IV quinine, quinidine
- Supportive care: Fluids, oxygen, blood transfusion

***P. vivax*/*ovale***:
- Chloroquine + Primaquine
- G6PD testing before primaquine
- Radical cure to prevent relapse

#### National Malaria Control Programme (NMCP)
**Objectives**: 
- Achieve elimination in low-endemic areas
- Reduce mortality by 90% by 2030

**Key Strategies**:
- LLIN (Long-Lasting Insecticidal Nets)
- IRS (Indoor Residual Spraying)
- Case management: RDT + ACT
- Larval source management
- Seasonal malaria chemoprevention (SMC)

### II. DENGUE FEVER AND DHF

#### Epidemiological Triangle
- **Agent**: Dengue virus (serotypes 1-4, Flavivirus)
- **Host**: All age groups, previous infection increases risk of DHF
- **Environment**: Urban, semi-urban areas, breeding sites

#### Vector
- **Primary**: *Aedes aegypti* (day-biting, container breeder)
- **Secondary**: *Aedes albopictus*
- **Breeding sites**: Artificial containers, tires, flower pots

#### Clinical Spectrum
**Dengue Fever (DF)**:
- High fever, severe headache, retro-orbital pain
- Myalgia, arthralgia, rash
- Hemorrhagic manifestations

**Dengue Hemorrhagic Fever (DHF)**:
- Plasma leakage: Pleural effusion, ascites
- Hemorrhagic manifestations
- Thrombocytopenia (<100,000/μL)
- Elevated hematocrit

**Dengue Shock Syndrome (DSS)**:
- Hypotension, narrow pulse pressure
- Signs of shock: Cold extremities, oliguria
- Mortality 12-44% without treatment

#### Diagnosis
- **NS1 antigen**: Early detection (days 1-7)
- **IgM antibody**: Late phase (days 5-7)
- **IgG antibody**: Past infection or secondary infection
- **Hematocrit**: Serial monitoring
- ** platelet count**: Daily monitoring

#### Treatment
- **Supportive**: Fluids, paracetamol (avoid aspirin/NSAIDs)
- **Monitoring**: Vital signs, hematocrit, urine output
- **IV fluids**: Crystalloids for plasma leakage
- **Blood products**: Platelet transfusion if bleeding

#### Prevention & Control
- **Vector control**: Source reduction, larvicides, fogging
- **Personal protection**: Repellents, protective clothing
- **Community participation**: 3S strategy (Search, Seal, Support)
- **Surveillance**: Sentinel sites, case reporting

### III. CHIKUNGUNYA

#### Epidemiological Triangle
- **Agent**: Chikungunya virus (Togavirus)
- **Host**: All age groups
- **Environment**: Tropical areas, urban settlements

#### Clinical Features
- **Sudden onset**: High fever, severe joint pain
- **Arthralgia**: Small joints, can persist for months
- **Maculopapular rash**: Face and trunk
- **Complications**: Meningoencephalitis, hepatitis

#### Vector Control
- *Aedes aegypti* and *Aedes albopictus*
- Similar to dengue control measures

### IV. JAPANESE ENCEPHALITIS

#### Epidemiological Triangle
- **Agent**: Japanese encephalitis virus (Flavivirus)
- **Host**: Children <15 years, pigs (amplifying hosts)
- **Environment**: Rural areas, rice fields, pig farms

#### Vector
- **Primary**: *Culex tritaeniorhynchus* (night-biting)
- **Breeding**: Rice fields, irrigation canals

#### Clinical Features
- **Incubation**: 5-15 days
- **Prodromal**: Fever, headache, vomiting
- **Neurological**: Altered consciousness, seizures, paralysis
- **Mortality**: 20-30% in clinical cases

#### Diagnosis & Prevention
- **Serology**: IgM capture ELISA
- **Vaccination**: Inactivated (JE) vaccine
- **Vector control**: Source reduction, personal protection
- **Pig vaccination**: Reduces human transmission

### V. FILARIASIS

#### Lymphatic Filariasis
- **Agents**: *Wuchereria bancrofti*, *Brugia malayi*, *Brugia timori*
- **Vector**: *Culex quinquefasciatus* (urban), *Anopheles* (rural)
- **Clinical**: Lymphedema, hydrocele, elephantiasis

#### Onchocerciasis (River Blindness)
- **Agent**: *Onchocerca volvulus*
- **Vector**: *Simulium* blackflies
- **Clinical**: Skin nodules, river blindness

#### Control Measures
- **Mass Drug Administration (MDA)**: Albendazole + DEC/IVM
- **Vector control**: Insecticide-treated nets
- **Individual treatment**: DEC, albendazole

### VI. LEISHMANIASIS

#### Visceral Leishmaniasis (Kala-azar)
- **Agent**: *Leishmania donovani* complex
- **Vector**: *Phlebotomus argentipes* (sandfly)
- **Clinical**: Fever, weight loss, splenomegaly, pancytopenia

#### Cutaneous Leishmaniasis
- **Agent**: Various *Leishmania* species
- **Clinical**: Skin ulcers, nodules
- **Self-limiting** in some species

#### Diagnosis & Treatment
- **Diagnosis**: Bone marrow aspirate, rK39 antigen test
- **Treatment**: Sodium stibogluconate, amphotericin B, miltefosine
- **Prevention**: Vector control, personal protection

---

## CHAPTER 21: ZOONOSES

### I. RABIES

#### Epidemiological Triangle
- **Agent**: Rabies virus (Lyssavirus)
- **Host**: Mammals, especially carnivores and bats
- **Environment**: Urban (dog-mediated), sylvatic (wildlife-mediated)

#### Transmission
- **Animal bites**: Most common route
- **Scratches**: With saliva contamination
- **Mucosal contact**: Rare but possible
- **Inhalation**: Bat caves, laboratory exposure

#### Clinical Features
**Furious Rabies**:
- Hydrophobia, aerophobia, hypersalivation
- Hallucinations, agitation, aggression
- spasms: Pharyngeal muscles

**Paralytic Rabies**:
- Ascending paralysis
- Muscle wasting
- Longer duration (7-10 days)

#### Post-Exposure Prophylaxis (PEP)
**Category I**: Touching/feeding animal
- **Action**: No treatment needed

**Category II**: Nibbling of uncovered skin
- **Action**: Wound washing + Vaccine

**Category III**: Bites, scratches, contamination
- **Action**: Wound washing + RIG + Vaccine

#### Treatment Protocol
**Wound Management**:
- Immediate washing (15 minutes)
- Antiseptic application (povidone-iodine)
- Avoid suturing if possible

**Vaccination**:
- **Essen regimen**: Days 0, 3, 7, 14, 28 (IM)
- **Oxford regimen**: Days 0, 3, 7, 14 (IM)
- **ID route**: WHO recommended, cost-effective

**Rabies Immunoglobulin (RIG)**:
- Human RIG (HRIG): 20 IU/kg
- Equine RIG (ERIG): 40 IU/kg
- Infiltrate around wound

#### Pre-Exposure Prophylaxis
- **Risk groups**: Veterinarians, laboratory workers
- **Schedule**: Days 0, 7, 21 or 28 (IM or ID)
- **Booster**: Based on antibody levels

### II. ANTHRAX

#### Epidemiological Triangle
- **Agent**: *Bacillus anthracis* (spore-forming bacterium)
- **Host**: Herbivores, humans
- **Environment**: Soil, contaminated animal products

#### Forms of Anthrax

**Cutaneous Anthrax (95%)**:
- Eschar with edema
- Black necrotic center
- Painless, non-tender

**Inhalational Anthrax**:
- "Woolsorter's disease"
- Fever, dyspnea, mediastinal widening
- High mortality (85-95%)

**Gastrointestinal Anthrax**:
- Nausea, vomiting, bloody diarrhea
- Abdominal pain, ascites
- Mortality 25-60%

#### Diagnosis & Treatment
- **Diagnosis**: Gram stain, culture, PCR
- **Treatment**: Penicillin, ciprofloxacin, doxycycline
- **Prevention**: Vaccination (animal), proper disposal

### III. BRUCELLOSIS

#### Epidemiological Triangle
- **Agent**: *Brucella* species (*melitensis*, *abortus*, *suis*, *canis*)
- **Host**: Cattle, goats, swine, dogs
- **Environment**: Unpasteurized dairy products

#### Clinical Features
- **Undulant fever**: Intermittent fever pattern
- **Musculoskeletal**: Arthralgia, spondylitis
- **Reproductive**: Orchitis, abortion in animals
- **Chronic**: Fatigue, depression

#### Diagnosis & Treatment
- **Diagnosis**: Blood culture, serology (SAT, ELISA)
- **Treatment**: Doxycycline + Rifampin (6 weeks)
- **Prevention**: Pasteurization, vaccination

### IV. LEPTOSPIROSIS

#### Epidemiological Triangle
- **Agent**: *Leptospira interrogans*
- **Host**: Rodents, domestic animals
- **Environment**: Contaminated water, soil

#### Clinical Features
- **Biphasic illness**:
  - **Phase 1**: Fever, myalgia, conjunctival suffusion
  - **Phase 2**: Meningitis, hepatitis, renal failure

#### Diagnosis & Treatment
- **Diagnosis**: Dark-field microscopy, MAT, PCR
- **Treatment**: Doxycycline, penicillin
- **Prevention**: Rodent control, protective equipment

### V. EMERGING ZOONOSES

#### Factors Driving Emergence
- **Environmental change**: Deforestation, urbanization
- **Climate change**: Altered vector distribution
- **Intensive agriculture**: High-density farming
- **Global travel**: Rapid pathogen spread
- **Antimicrobial resistance**: Treatment challenges

#### Examples of Emerging Zoonoses
- **Nipah virus**: Fruit bats to humans via pigs/dates
- **H5N1 avian influenza**: Poultry to humans
- **Ebola virus disease**: Wildlife to humans
- **SARS**: Bats to civets to humans
- **COVID-19**: Likely bat to humans

#### Surveillance & Response
- **One Health approach**: Human, animal, environment health
- **Early warning systems**: Syndromic surveillance
- **Cross-sector collaboration**: Human and veterinary sectors
- **Research**: Diagnostic tools, vaccines, therapeutics

---

## CHAPTER 22: SURFACE INFECTIONS

### I. TRACHOMA

#### Epidemiological Triangle
- **Agent**: *Chlamydia trachomatis* (A, B, C serotypes)
- **Host**: Children <10 years, particularly girls
- **Environment**: Poor hygiene, water scarcity, crowding

#### Clinical Features
- **Active trachoma**: 
  - Follicular and papillary reactions
  - Pannus formation
  - Discharge and irritation

**Trachomatous trichiasis**:
- Eyelashes turn inward
- Corneal abrasion and scarring

**End-stage trachoma**:
- Corneal opacity
- Blindness

#### Diagnosis
- **Clinical**: WHO simplified grading system
- **Laboratory**: PCR, antigen detection
- **Screening**: Community-based surveys

#### Control Measures (SAFE Strategy)
**S - Surgery**: Trichiasis correction
**A - Antibiotics**: Azithromycin mass treatment
**F - Facial cleanliness**: Hygiene promotion
**E - Environmental improvement**: Water, sanitation

### II. YAWS

#### Epidemiological Triangle
- **Agent**: *Treponema pallidum pertenue*
- **Host**: Children <15 years
- **Environment**: Tropical, humid, poor hygiene

#### Clinical Stages
**Primary yaws**:
- Papule at inoculation site
- Ulcer with raspberry appearance
- Regional lymphadenopathy

**Secondary yaws**:
- Generalized skin lesions
- "Yucca flower" appearance
- Palmar/plantar hyperkeratosis

**Tertiary yaws**:
- Bone deformities
- Gummatous lesions

#### Diagnosis & Treatment
- **Diagnosis**: Serology (VDRL/RPR), dark-field microscopy
- **Treatment**: Single dose benzathine penicillin
- **Prevention**: Improved hygiene, mass treatment

### III. LEPROSY (HANSEN'S DISEASE)

#### Epidemiological Triangle
- **Agent**: *Mycobacterium leprae* (acid-fast bacillus)
- **Host**: Variable susceptibility, genetic factors
- **Environment**: Overcrowding, poor living conditions

#### Classification Systems

**Ridley-Jopling Classification**:
- **TT**: Tuberculoid leprosy (1-2 lesions)
- **BT**: Borderline tuberculoid
- **BB**: Borderline borderline
- **BL**: Borderline lepromatous
- **LL**: Lepromatous leprosy (numerous lesions)

**WHO Classification**:
- **Paucibacillary (PB)**: 1-5 lesions (TT, BT)
- **Multibacillary (MB)**: >5 lesions (BB, BL, LL)

#### Clinical Features
**Skin lesions**: Hypopigmented, anesthetic patches
**Nerve involvement**: Thickened nerves, sensory loss
** Complications**: Claw hand, foot drop, facial palsy
**Eye involvement**: Lagophthalmos, corneal ulceration

#### Diagnosis
- **Clinical**: Skin lesions + nerve involvement
- **Skin smear**: AFB detection (slit-skin smear)
- **Skin biopsy**: Histopathology
- **Nerve biopsy**: In selected cases

#### Treatment Protocols

**PB leprosy**:
- Dapsone 100 mg daily + Rifampicin 600 mg monthly (6 months)

**MB leprosy**:
- Dapsone 100 mg daily + Rifampicin 600 mg monthly + Clofazimine 300 mg monthly (12 months)

**MDT Multidrug Therapy**: Prevents drug resistance, ensures cure

#### National Leprosy Elimination Programme (NLEP)

**Objectives**: Achieve elimination (<1 case/10,000 population)
**Strategies**:
- Early case detection
- Regular MDT supply
- Rehabilitation services
- IEC activities
- Training of health workers

**Monitoring**: 
- Prevalence rate
- New case detection rate
- Disability grade II among new cases
- Completion rate of treatment

### IV. SCABIES AND OTHER SKIN INFECTIONS

#### Scabies
- **Agent**: *Sarcoptes scabiei* var. *hominis*
- **Transmission**: Prolonged skin contact, sexual contact
- **Clinical**: Intense pruritus, burrows, papules
- **Distribution**: Web spaces, wrists, genitalia

**Norwegian scabies**: Crusted form in immunocompromised
**Diagnosis**: Microscopic examination of scrapings
**Treatment**: Permethrin 5% cream, oral ivermectin

#### Other Skin Infections
**Impetigo**: *Staph aureus*, *Strep pyogenes*
**Cellulitis**: *Strep pyogenes*, *Staph aureus*
**Tinea infections**: Dermatophytes (*Trichophyton*, *Microsporum*, *Epidermophyton*)
**Herpes simplex**: HSV-1, HSV-2
**Varicella-zoster**: Chickenpox, shingles

---

## CHAPTER 23: SEXUALLY TRANSMITTED INFECTIONS

### I. SYPHILIS

#### Epidemiological Triangle
- **Agent**: *Treponema pallidum* (spirochete)
- **Host**: Sexually active individuals
- **Environment**: Unprotected sexual contact, multiple partners

#### Stages of Syphilis

**Primary Syphilis**:
- **Chancre**: Painless ulcer with raised edges
- **Location**: Genitalia, perineum, extragenital sites
- **Duration**: 3-6 weeks, heals spontaneously

**Secondary Syphilis**:
- **Rash**: Maculopapular, non-itchy
- **Distribution**: Trunk, palms, soles
- **Other**: Mucous patches, condyloma lata

**Latent Syphilis**:
- **Early**: <1 year duration
- **Late**: >1 year duration
- **Asymptomatic**: Serological evidence only

**Tertiary Syphilis**:
- **Gummatous**: Soft, granulomatous lesions
- **Cardiovascular**: Aortitis, aneurysms
- **Neurosyphilis**: Tabes dorsalis, general paresis

#### Diagnosis
**Direct methods**:
- Dark-field microscopy
- Direct fluorescent antibody test

**Serological tests**:
- **Non-treponemal**: VDRL, RPR (screening)
- **Treponemal**: TPHA, FTA-ABS (confirmatory)
- **TPPA**: Treponema pallidum particle agglutination

#### Treatment
- **Primary/Secondary/Early latent**: Benzathine penicillin G 2.4 million units IM (single dose)
- **Late latent/Tertiary**: Benzathine penicillin G 2.4 million units IM weekly × 3 weeks
- **Neurosyphilis**: Aqueous crystalline penicillin G 18-24 million units/day IV × 10-14 days

### II. GONORRHEA

#### Epidemiological Triangle
- **Agent**: *Neisseria gonorrhoeae* (Gram-negative diplococcus)
- **Host**: Sexually active individuals
- **Environment**: Unprotected sexual contact

#### Clinical Features
**Men**:
- Urethral discharge (purulent)
- Dysuria
- Epididymitis (complication)

**Women**:
- Cervicitis with discharge
- Pelvic inflammatory disease (PID)
- Infertility (complication)

**Other manifestations**:
- Pharyngeal infection
- Rectal infection
- Disseminated gonococcal infection (DGI)

#### Diagnosis
- **Gram stain**: Gram-negative diplococci within PMNs
- **Culture**: Thayer-Martin medium
- **NAAT**: Nucleic acid amplification tests (preferred)
- **Antimicrobial susceptibility**: Important for treatment

#### Treatment
**Uncomplicated gonorrhea**:
- Ceftriaxone 500mg IM single dose + Azithromycin 1g single dose
- Alternative: Ceftriaxone 1g IM + Doxycycline 100mg BID × 7 days

**Complicated gonorrhea**: Extended treatment regimens
**Partners**: Treat all sexual partners within 60 days

### III. CHLAMYDIA

#### Epidemiological Triangle
- **Agent**: *Chlamydia trachomatis* (serotypes D-K)
- **Host**: Sexually active individuals
- **Environment**: Unprotected sexual contact

#### Clinical Features
**Asymptomatic infection**: 70-80% cases
**Men**: Urethritis, epididymitis
**Women**: Cervicitis, PID, infertility
**Complications**: Reactive arthritis, Fitz-Hugh-Curtis syndrome

#### Diagnosis
- **NAAT**: Most sensitive and specific
- **Culture**: Gold standard but less available
- **Antigen detection**: EIA, DFA

#### Treatment
- **Azithromycin**: 1g single dose (preferred)
- **Doxycycline**: 100mg BID × 7 days
- **Partners**: Treat all sexual partners within 60 days

### IV. HIV/AIDS

#### Epidemiological Triangle
- **Agent**: Human Immunodeficiency Virus (HIV-1, HIV-2)
- **Host**: All age groups, high-risk behaviors
- **Environment**: High-risk practices, blood exposure

#### Transmission Routes
**Sexual transmission**: Unprotected vaginal/anal intercourse
**Bloodborne**: Needle sharing, blood transfusion
**Mother-to-child**: Pregnancy, delivery, breastfeeding
**Occupational**: Needlestick injuries

#### Clinical Course
**Acute HIV infection**: Flu-like illness (2-4 weeks post-exposure)
**Clinical latency**: Asymptomatic period (8-10 years)
**AIDS**: CD4 count <200 cells/μL, opportunistic infections

#### Opportunistic Infections
**Bacterial**: TB, bacterial pneumonia
**Fungal**: PCP pneumonia, candidiasis
**Viral**: HSV, CMV, hepatitis B/C
**Parasitic**: Toxoplasmosis, cryptosporidiosis

#### Diagnosis
**Screening tests**:
- ELISA/EIA (4th generation)
- Rapid tests
- OraQuick oral fluid test

**Confirmatory tests**:
- Western blot
- HIV-1 RNA PCR
- Immunofluorescence assay

#### Treatment
**Antiretroviral Therapy (ART)**:
- **NRTI**: Lamivudine, tenofovir, zidovudine
- **NNRTI**: Efavirenz, nevirapine
- **PI**: Ritonavir, lopinavir/ritonavir
- **Integrase inhibitors**: Raltegravir, dolutegravir

**Treatment goals**:
- Viral suppression (<200 copies/mL)
- CD4 count recovery (>500 cells/μL)
- Prevent progression to AIDS
- Reduce transmission

#### National AIDS Control Programme (NACP)

**Phase I (1992-1999)**:
- Blood safety
- Condom promotion
- STD control

**Phase II (1999-2007)**:
- Targeted interventions
- Surveillance systems
- Care and support

**Phase III (2007-2012)**:
- Universal access
- ART scale-up
- Prevention of parent-to-child transmission

**Phase IV (2012-2017)**:
- Consolidated prevention
- Treatment as prevention
- Key populations focus

**Current strategies**:
- 90-90-90 targets by 2020
- Test and treat approach
- PrEP for high-risk groups
- Integration with TB/Hepatitis programs

### V. OTHER STIs

#### Chancroid
- **Agent**: *Haemophilus ducreyi*
- **Clinical**: Painful genital ulcer, inguinal adenopathy
- **Treatment**: Azithromycin 1g single dose, ceftriaxone 250mg IM

#### Lymphogranuloma Venereum (LGV)
- **Agent**: *Chlamydia trachomatis* (L1, L2, L3)
- **Clinical**: Painless papule → painless lymphadenopathy
- **Treatment**: Doxycycline 100mg BID × 21 days

#### Genital Herpes
- **Agent**: HSV-1, HSV-2
- **Clinical**: Vesicular lesions, pain, itching
- **Treatment**: Acyclovir, valacyclovir, famciclovir
- **Suppression**: Daily antiviral therapy

---

## CHAPTER 24: OTHER INFECTIONS

### I. TETANUS

#### Epidemiological Triangle
- **Agent**: *Clostridium tetani* (anaerobic, spore-forming)
- **Host**: Unvaccinated individuals, elderly, drug users
- **Environment**: Soil, dust, animal excreta

#### Transmission
- **Wound contamination**: Soil, rust, organic matter
- **Neonatal**: Umbilical cord contamination
- **Iatrogenic**: Surgical procedures, injections
- **Ear infections**: Chronic otitis media

#### Pathogenesis
- **Toxin production**: Tetanospasmin (neurotoxin)
- **Mechanism**: Blocks inhibitory neurotransmitters
- **Result**: Uncontrolled muscle contraction

#### Clinical Features

**Local tetanus**: Muscle spasms at wound site
**Generalized tetanus**: Most common form
- **Trismus** (lockjaw): Masseter muscle spasm
- **Risus sardonicus**: Facial muscle spasm
- **Opisthotonos**: Arched back
- **Generalized spasms**: Triggered by stimuli

**Neonatal tetanus**:
- **Source**: Contaminated umbilical stump
- **Symptoms**: Poor feeding, rigidity, spasms
- **High mortality**: 80-90% without treatment

**Cephalic tetanus**: Cranial nerve involvement
**Puerperal tetanus**: Postpartum, post-abortion

#### Diagnosis
- **Clinical**: Muscle spasms, rigidity history
- **Laboratory**: Wound culture, toxin detection
- **Differential**: Dystonia, meningitis, seizures

#### Treatment
**Immediate measures**:
- **Human Tetanus Immunoglobulin (HTIG)**: 500 units IM
- **Wound debridement**: Remove necrotic tissue
- **Antibiotics**: Metronidazole, penicillin

**Supportive care**:
- **Muscle relaxants**: Diazepam, baclofen
- **Ventilatory support**: For respiratory compromise
- **Autonomic instability**: Beta-blockers, clonidine

**Prevention**:
- **Active immunization**: DTaP, Td, Tdap vaccines
- **Wound management**: Proper cleaning, vaccination
- **Passive immunization**: TIG for contaminated wounds

### II. VIRAL ENCEPHALITIS

#### Japanese Encephalitis (JE)
- **Agent**: Flavivirus
- **Vector**: *Culex* mosquitoes
- **Clinical**: Acute onset fever, altered consciousness, seizures
- **Diagnosis**: IgM ELISA, PCR
- **Treatment**: Supportive care, no specific antiviral

#### Herpes Simplex Encephalitis (HSE)
- **Agent**: HSV-1 (adults), HSV-2 (neonates)
- **Clinical**: Fever, headache, altered mental status, seizures
- **Diagnosis**: CSF PCR (gold standard)
- **Treatment**: IV acyclovir (10 mg/kg Q8H × 14-21 days)

#### Rabies Encephalitis
- **Agent**: Rabies virus
- **Prodrome**: Fever, headache, anxiety, hallucinations
- **Progressive**: Confusion, agitation, paralysis
- **Fatal**: Once symptoms develop

#### Enteroviral Encephalitis
- **Agent**: Echovirus, coxsackievirus
- **Seasonal**: Summer-autumn
- **Clinical**: Fever, headache, meningeal signs
- **Self-limiting**: Supportive care

### III. MENINGOCOCCAL INFECTIONS

#### Epidemiological Triangle
- **Agent**: *Neisseria meningitidis* (serogroups A, B, C, W, Y)
- **Host**: Children <5 years, adolescents
- **Environment**: Crowding, close contact

#### Clinical Spectrum

**Meningococcal carriage**: Asymptomatic (5-25%)
**Meningococcemia**:
- Fever, petechial rash, hypotension
- Waterhouse-Friderichsen syndrome (adrenal hemorrhage)
- Purpura fulminans

**Meningococcal meningitis**:
- Fever, headache, neck stiffness
- Altered consciousness
- Photophobia

**Other forms**: Pneumonia, arthritis, conjunctivitis

#### Diagnosis
- **CSF analysis**: Gram-negative diplococci
- **Culture**: Blood, CSF, nasopharyngeal
- **PCR**: Rapid detection
- **Antigen detection**: Latex agglutination

#### Treatment
- **Third-generation cephalosporins**: Ceftriaxone, cefotaxime
- **Penicillin G**: Alternative if susceptible
- **Adjunctive dexamethasone**: Controversial

#### Prevention
**Vaccination**:
- **Conjugate vaccines**: MenA, MenC, MenACWY
- **Polysaccharide vaccines**: Limited duration
- **Serogroup B vaccines**: Recent introduction

**Chemoprophylaxis**:
- **Rifampin**: 600mg BID × 2 days
- **Ciprofloxacin**: 500mg single dose
- **Ceftriaxone**: 250mg IM single dose

### IV. VIRAL HEMORRHAGIC FEVERS

#### Characteristics
- **Agent**: Various viruses (Arenavirus, Filovirus, Bunyavirus, Flavivirus)
- **Transmission**: Animal reservoirs, person-to-person
- **Clinical**: Fever, hemorrhage, shock
- **High mortality**: 25-90% depending on virus

#### Ebola Virus Disease (EVD)
- **Agent**: Ebolavirus
- **Transmission**: Direct contact with body fluids
- **Clinical**: Fever, hemorrhage, organ failure
- **Mortality**: Up to 90%
- **Treatment**: Supportive, experimental therapies

#### Crimean-Congo Hemorrhagic Fever
- **Agent**: *Nairovirus*
- **Vector**: *Hyalomma* ticks
- **Endemic**: Africa, Asia, Europe
- **Mortality**: 10-40%

#### Management
- **Isolation**: Strict barrier nursing
- **Supportive care**: Fluids, blood products
- **Experimental treatments**: Antivirals, monoclonal antibodies
- **Prevention**: Vector control, personal protection

---

## CHAPTER 25: DISASTERS

### I. NATURAL DISASTERS

#### Classification
**Meteorological**: Cyclones, hurricanes, tornadoes
**Geological**: Earthquakes, volcanic eruptions, tsunamis
**Climatological**: Floods, droughts, wildfires
**Biological**: Epidemics, pest outbreaks

#### Earthquake Response
**Immediate (0-72 hours)**:
- **Search and rescue**: Extricate trapped victims
- **Medical triage**: START protocol
- **Casualty management**: Trauma care, shock prevention
- **Logistics**: Food, water, shelter, communications

**Short-term (3-14 days)**:
- **Epidemiological surveillance**: Disease outbreak monitoring
- **Water and sanitation**: Ensure safe drinking water
- **Nutrition**: Food security, supplementation
- **Shelter**: Temporary housing, protection

**Long-term (>14 days)**:
- **Reconstruction**: Infrastructure rebuilding
- **Health system restoration**: Primary healthcare services
- **Mental health**: Psychological support, counseling
- **Preparedness**: Community resilience building

#### Flood Management
**Pre-flood measures**:
- **Early warning systems**: River level monitoring
- **Evacuation planning**: Safe shelter identification
- **Community preparedness**: Emergency supplies

**During flood**:
- **Rescue operations**: Water-based evacuation
- **Medical emergencies**: Drowning, trauma, hypothermia
- **Waterborne diseases**: Cholera, hepatitis A

**Post-flood**:
- **Vector control**: Mosquito breeding prevention
- **Water purification**: Chlorination, filtration
- **Vector-borne diseases**: Malaria, dengue prevention

### II. MAN-MADE DISASTERS

#### Industrial Accidents
**Chemical disasters**:
- **Bhopal gas tragedy (1984)**: Methyl isocyanate leak
- **Health effects**: Respiratory, neurological, ophthalmological
- **Emergency response**: Evacuation, decontamination

**Radiological emergencies**:
- **Chernobyl (1986)**, Fukushima (2011)
- **Health effects**: Radiation sickness, cancer
- **Management**: Decontamination, iodine prophylaxis

#### Terrorist Events
**Biological terrorism**:
- **Anthrax letters (2001)**: Anthrax spores
- **Response**: Investigation, prophylaxis, treatment

**Chemical terrorism**:
- **Nerve agents**: Sarin, VX
- **Clinical**: Cholinergic crisis
- **Treatment**: Atropine, pralidoxime

**Radiological dispersion devices (RDDs)**:
- **Dirty bombs**: Radiation exposure
- **Management**: Evacuation, decontamination

### III. EPIDEMICS DURING DISASTERS

#### Common Outbreaks
**Waterborne diseases**:
- **Cholera**: Contaminated water
- **Typhoid**: Poor sanitation
- **Hepatitis A**: Fecal-oral transmission

**Vector-borne diseases**:
- **Malaria**: Stagnant water breeding sites
- **Dengue**: Container breeding in debris
- **Leishmaniasis**: Rodent displacement

**Respiratory infections**:
- **Tuberculosis**: Overcrowding in shelters
- **Pneumonia**: Malnutrition, cold exposure
- **Influenza**: Close contact in camps

#### Prevention Strategies
**Water, sanitation, hygiene (WASH)**:
- **Safe water**: Chlorination, filtration
- **Sanitation**: Improved excreta disposal
- **Hygiene**: Hand washing promotion

**Vector control**:
- **Source reduction**: Remove breeding sites
- **Larviciding**: Chemical/biological control
- **Adulticiding**: Space spraying

**Surveillance systems**:
- **Early warning**: Syndromic surveillance
- **Rapid response**: Outbreak investigation teams
- **Laboratory support**: Diagnostic capacity

### IV. EMERGENCY MEDICAL RESPONSE

#### Triage Systems

**START Triage** (Simple Triage and Rapid Treatment):
- **Red (Immediate)**: Life-threatening but salvageable
- **Yellow (Delayed)**: Serious but stable
- **Green (Minor)**: Walking wounded
- **Black (Expectant)**: Deceased or unsalvageable

**JumpSTART** (Pediatric modification):
- **Modified for children**: Age-specific considerations
- **Respiratory assessment**: Apnea, respiratory rate
- **Circulation**: Pulse presence, capillary refill

#### Casualty Management
**Golden hour concept**: Definitive care within 60 minutes
**Advanced trauma life support (ATLS)**:
- **Primary survey**: ABCDE approach
- **Secondary survey**: Head-to-toe examination
- **Definitive care**: Specialized treatment

**Mass casualty management**:
- **Role definition**: Incident command system
- **Resource allocation**: Scarce resource management
- **Documentation**: Medical records, tracking

#### Hospital Preparedness
**Surge capacity**:
- **Surge up**: Expanding existing capacity
- **Surge forward**: Alternate care sites
- **Surge down**: Load shedding

**Hospital incident command system (HICS)**:
- **Command structure**: Clear hierarchy
- **Communication**: Internal/external coordination
- **Resource management**: Essential supplies

---

## CHAPTER 26: EMERGING AND RE-EMERGING DISEASES

### I. COVID-19 (DETAILED)

#### SARS-CoV-2 Characteristics
- **Family**: Coronaviridae
- **Structure**: Enveloped, positive-sense RNA virus
- **Spike protein**: Mediates host cell entry via ACE2
- **Genomic variants**: Alpha, Beta, Gamma, Delta, Omicron

#### Epidemiological Evolution
**Phase 1**: Wuhan outbreak (December 2019)
**Phase 2**: Global spread (March 2020)
**Phase 3**: Vaccine development (2020-2021)
**Phase 4**: Variant emergence (2021-2022)
**Phase 5**: Endemic phase (2023 onwards)

#### Clinical Spectrum
**Asymptomatic infection**: 40-45% cases
**Mild disease**: 80% of symptomatic cases
- Fever, cough, fatigue, anosmia, ageusia

**Severe disease**: 15% cases
- Dyspnea, hypoxia, bilateral pneumonia
- Hospitalization, oxygen support

**Critical disease**: 5% cases
- ARDS, septic shock, multi-organ failure
- ICU care, mechanical ventilation

**Long COVID**: Post-acute sequelae
- Persistent fatigue, cognitive impairment
- Multi-system involvement

#### Diagnosis
**Molecular testing**:
- **RT-PCR**: Gold standard (nasopharyngeal swab)
- **Real-time PCR**: Quantitative viral load
- **Loop-mediated isothermal amplification (LAMP)**

**Antigen detection**:
- **Rapid antigen tests**: Point-of-care
- **Sensitivity**: Lower than PCR
- **Specificity**: High for active infection

**Serology**:
- **IgM/IgG antibodies**: Infection history
- **Neutralizing antibodies**: Immunity assessment
- **Limitations**: Timing of infection unclear

#### Treatment Evolution
**Supportive care**:
- **Oxygen therapy**: Nasal cannula to mechanical ventilation
- **Anticoagulation**: VTE prophylaxis
- **Corticosteroids**: Dexamethasone in severe cases

**Antiviral therapies**:
- **Remdesivir**: RNA polymerase inhibitor
- **Molnupiravir**: Nucleoside analog
- **Paxlovid**: Protease inhibitor combination

**Monoclonal antibodies**:
- **Early use**: Bamlanivimab, casirivimab/imdevimab
- **Effectiveness**: Waned against variants

#### Prevention Strategies
**Non-pharmaceutical interventions (NPIs)**:
- **Masks**: Surgical, N95, cloth masks
- **Physical distancing**: 1-2 meters spacing
- **Hand hygiene**: Soap, sanitizer
- **Ventilation**: Outdoor gatherings preferred

**Vaccination**:
- **mRNA vaccines**: Pfizer-BioNTech, Moderna
- **Viral vector**: AstraZeneca, Johnson & Johnson
- **Inactivated**: Sinopharm, Sinovac
- **Heterologous boosting**: Improved immunity

**Global response**:
- **WHO coordination**: International Health Regulations
- **COVAX**: Global vaccine access initiative
- **Travel restrictions**: Quarantine protocols
- **Digital health**: Contact tracing apps

#### Long-term Impact
**Healthcare systems**:
- **Surge capacity**: ICU expansion, resource allocation
- **Telemedicine**: Remote healthcare delivery
- **Supply chain**: PPE, ventilator shortages

**Economic consequences**:
- **GDP impact**: Global recession
- **Unemployment**: Service sector losses
- **Education disruption**: Remote learning
- **Mental health**: Increased anxiety, depression

### II. NIPAH VIRUS

#### Epidemiological Triangle
- **Agent**: Nipah virus (Paramyxoviridae)
- **Host**: Fruit bats (*Pteropus* species)
- **Environment**: Fruit orchards, pig farms

#### Transmission
- **Zoonotic**: Fruit bat to human
- **Intermediate**: Pig to human
- **Human-to-human**: Respiratory secretions, close contact
- **Foodborne**: Contaminated date palm sap

#### Clinical Features
**Incubation**: 4-14 days
**Initial symptoms**: Fever, headache, myalgia
**Neurological**: Encephalitis, seizures, altered consciousness
**Respiratory**: Cough, dyspnea (in some cases)
**Mortality**: 40-75% in outbreaks

#### Outbreaks
**Malaysia (1998-1999)**: 265 cases, 105 deaths
**Bangladesh (2001-ongoing)**: Annual outbreaks
**India (2018)**: Kerala outbreak, 19 deaths

#### Diagnosis & Management
- **RT-PCR**: Virus detection in CSF, throat swabs
- **Serology**: IgM ELISA, neutralization assays
- **Supportive care**: No specific antiviral
- **Prevention**: Avoid raw date palm sap, pig farm hygiene

### III. EBOLA VIRUS DISEASE

#### Epidemiological Triangle
- **Agent**: Ebolavirus (Filoviridae)
- **Host**: Fruit bats (reservoir)
- **Environment**: Tropical rainforests

#### Transmission
- **Zoonotic**: Bat to human
- **Human-to-human**: Direct contact with body fluids
- **Nosocomial**: Healthcare transmission
- **Sexual transmission**: Semen persistence

#### Clinical Features
**Incubation**: 2-21 days
**Early phase**: Fever, headache, myalgia, sore throat
**Late phase**: Diarrhea, vomiting, rash, hemorrhage
**Shock**: Multi-organ failure, death
**Survivors**: Prolonged virus persistence

#### Management
**Supportive care**:
- **Fluid resuscitation**: Electrolyte replacement
- **Blood products**: Transfusion, plasma exchange
- **Pain management**: Symptomatic treatment

**Experimental therapies**:
- **Monoclonal antibodies**: REGN-EB3, mAb114
- **Antivirals**: Remdesivir, favipiravir

#### Prevention
**Vaccination**:
- **rVSV-ZEBOV**: Single-dose vaccine
- **Ring vaccination**: Contact tracing and immunization

**Infection control**:
- **Barrier nursing**: PPE, isolation
- **Safe burial**: Body handling protocols
- **Community engagement**: Trust building

### IV. ANTIMICROBIAL RESISTANCE (AMR)

#### Global Threat
- **WHO priority pathogens**: ESKAPE organisms
- **Economic impact**: $100 trillion by 2050
- **Mortality projection**: 10 million deaths annually

#### Mechanisms of Resistance
**Antibiotic degradation**: Beta-lactamases
**Efflux pumps**: Drug expulsion from bacteria
**Target modification**: Altered binding sites
**Reduced permeability**: Membrane changes

#### Key Resistance Patterns
**ESBL**: Extended-spectrum beta-lactamases
**CRE**: Carbapenem-resistant Enterobacterales
**MRSA**: Methicillin-resistant *S. aureus*
**VRE**: Vancomycin-resistant enterococci
**XDR-TB**: Extensively drug-resistant tuberculosis

#### Surveillance Systems
**GLASS**: Global Antimicrobial Resistance Surveillance System
**National programs**: Country-specific surveillance
**Laboratory capacity**: Diagnostic capability
**Data sharing**: International collaboration

#### Prevention Strategies
**Antibiotic stewardship**:
- **Judicious use**: Evidence-based prescribing
- **Diagnostic stewardship**: Appropriate testing
- **Infection prevention**: Hand hygiene, contact precautions
- **Surveillance**: Resistance monitoring

**Research & Development**:
- **New antibiotics**: Pipeline development
- **Rapid diagnostics**: Point-of-care testing
- **Alternative therapies**: Phage therapy, immunotherapy

### V. CLIMATE CHANGE AND INFECTIOUS DISEASES

#### Environmental Changes
**Temperature increase**: Expands vector ranges
**Precipitation changes**: Alters breeding habitats
**Sea level rise**: Coastal flooding, saltwater intrusion
**Extreme weather**: Droughts, floods, storms

#### Vector-Borne Diseases
**Malaria**:
- **Altitude expansion**: Mosquito range extension
- **Seasonal patterns**: Changed transmission seasons
- **Drug resistance**: Temperature-related selection

**Dengue**:
- **Urban expansion**: *Aedes* habitat proliferation
- **Seasonal variation**: Monsoon pattern changes
- **Severe disease**: Climate-related factors

**Lyme disease**:
- **Range expansion**: Tick distribution changes
- **Seasonal activity**: Extended transmission season

#### Water-Borne Diseases
**Cholera**:
- **Coastal outbreaks**: Warm water, plankton
- **Flooding events**: Contamination of water sources

**Cryptosporidiosis**:
- **Extreme weather**: Water treatment failures
- **Temperature effects**: Parasite survival

#### Food-Borne Diseases
**Salmonellosis**:
- **Temperature effects**: Bacterial growth
- **Food chain**: Agricultural impacts

**Campylobacter**:
- **Seasonal patterns**: Summer peaks
- **Climate variability**: Outbreak frequency

#### Adaptation Strategies
**Health systems**:
- **Early warning**: Climate-based surveillance
- **Response capacity**: Emergency preparedness
- **Resilience building**: Infrastructure strengthening

**Vector control**:
- **Integrated approaches**: Chemical, biological, environmental
- **Climate adaptation**: Changing control strategies
- **Surveillance**: Vector distribution monitoring

---

## CHAPTER 27: NOSOCOMIAL INFECTIONS

### I. HOSPITAL-ACQUIRED INFECTIONS

#### Definition
- **Nosocomial infection**: Infection acquired during hospital stay
- **Not present/ incubating** at admission
- **Manifests >48 hours** after admission
- **Healthcare-associated**: Related to medical care

#### Classification by Site
**Surgical site infections (SSI)**:
- **Superficial**: Skin and subcutaneous tissue
- **Deep**: Fascia and muscle layers
- **Organ/space**: Any other part of anatomy

**Central line-associated bloodstream infections (CLABSI)**:
- **Catheter-related**: Primary bacteremia
- **Catheter tip colonization**: Sepsis source

**Ventilator-associated pneumonia (VAP)**:
- **Tube placement**: >48 hours
- **Pneumonia onset**: After intubation

**Catheter-associated urinary tract infections (CAUTI)**:
- **Indwelling catheter**: Risk factor
- **Symptomatic UTI**: With laboratory confirmation

#### Risk Factors
**Patient-related**:
- Age extremes (neonates, elderly)
- Immune suppression, malnutrition
- Chronic diseases (diabetes, renal failure)
- Severity of underlying illness

**Procedure-related**:
- Invasive procedures
- Prolonged hospitalization
- Multiple antibiotics use
- Intensive care unit stay

**Healthcare worker-related**:
- Hand hygiene compliance
- Aseptic technique
- Workload and staffing ratios
- Knowledge and training

### II. INFECTION CONTROL MEASURES

#### Standard Precautions
**Hand hygiene**:
- **Soap and water**: Visible soiling
- **Alcohol-based rub**: Routine decontamination
- **WHO 5 Moments**: Before patient contact, before aseptic procedure, after body fluid exposure, after patient contact, after patient environment

**Personal protective equipment (PPE)**:
- **Gloves**: Patient contact, body fluid exposure
- **Masks**: Respiratory protection, surgical procedures
- **Gowns**: Protect clothing, direct contact
- **Eye protection**: Splash risk procedures

**Respiratory hygiene/cough etiquette**:
- **Source control**: Cover cough/sneeze
- **Mask use**: Symptomatic patients
- **Spatial separation**: Triage area placement

#### Transmission-Based Precautions

**Contact Precautions**:
- **MRSA, VRE**: Direct contact transmission
- **Private room**: Preferred accommodation
- **Dedicated equipment**: Prevent cross-contamination

**Droplet Precautions**:
- **Influenza, pertussis**: Large particle transmission
- **Surgical mask**: Within 3 feet of patient
- **Private room**: Respiratory infections

**Airborne Precautions**:
- **Tuberculosis, measles**: Small particle transmission
- **N95 respirator**: Fit-tested, seal-checked
- **Negative pressure room**: Specialized ventilation

### III. STERILIZATION AND DISINFECTION

#### Levels of Processing

**Critical items**:
- **Definition**: Enter sterile tissue/cascular system
- **Method**: Sterilization (steam, ethylene oxide)
- **Examples**: Surgical instruments, implants

**Semi-critical items**:
- **Definition**: Contact mucous membranes
- **Method**: High-level disinfection
- **Examples**: Endoscopes, respiratory equipment

**Non-critical items**:
- **Definition**: Contact intact skin
- **Method**: Low-level disinfection
- **Examples**: Bed rails, stethoscopes

#### Sterilization Methods

**Steam sterilization**:
- **Temperature**: 121°C (250°F) for 15-20 minutes
- **Pressure**: 15-20 psi
- **Indicators**: Biological, chemical, physical

**Ethylene oxide (ETO)**:
- **Heat-sensitive items**: Medical devices
- **Aeration time**: Required for gas removal
- **Carcinogenic**: Worker safety concerns

**Hydrogen peroxide plasma**:
- **Low-temperature**: No toxic residues
- **Compatible items**: Electronics, plastics
- **Effective**: Against all microorganisms

#### Disinfectant Selection

**High-level disinfectants**:
- **Glutaraldehyde**: Endoscope processing
- **Hydrogen peroxide**: Broad-spectrum activity
- **Peracetic acid**: Sterilization capability

**Intermediate-level disinfectants**:
- **70% isopropyl alcohol**: Surface disinfection
- **Phenolics**: Environmental surfaces
- **Quaternary ammonium compounds**: Low-level activity

**Low-level disinfectants**:
- **Bleach (sodium hypochlorite)**: 0.1% concentration
- **Alcohol**: 70% concentration
- **Hydrogen peroxide**: 3% concentration

### IV. ANTIBIOTIC STEWARDSHIP

#### Principles
**Optimal selection**: Narrowest spectrum, appropriate duration
**Dose optimization**: PK/PD principles
**De-escalation**: Narrow therapy based on culture results
**Duration minimization**: Shortest effective course

#### Core Elements (CDC)
**Leadership commitment**: Administrative support
**Accountability**: Designated stewardship leader
**Drug expertise**: ID physician/pharmacist
**Action**: Intervention implementation
**Tracking**: Monitoring and reporting
**Reporting**: Feedback to prescribers
**Education**: Ongoing training

#### Interventions
**Prospective audit and feedback**:
- **Real-time review**: Antimicrobial orders
- **Intervention**: Recommendations to prescriber
- **Acceptance tracking**: Compliance monitoring

**Formulary restriction**:
- **Restricted antibiotics**: Prior approval required
- **Pre-authorization**: ID physician approval
- **Automatic stop orders**: Duration limits

**Antibiotic time-out**:
- **48-hour review**: Therapy assessment
- **Culture results**: Narrowing spectrum
- **Duration adjustment**: Shortening therapy

#### Metrics
**Process measures**:
- **Appropriate prescribing**: Indications, selection, duration
- **De-escalation rates**: Spectrum narrowing
- **IV-to-PO conversion**: Route optimization

**Outcome measures**:
- **Clostridioides difficile rates**: Infection reduction
- **Resistance rates**: Susceptibility trends
- **Length of stay**: Healthcare utilization
- **Mortality**: Patient outcomes

### V. HOSPITAL INFECTION CONTROL COMMITTEES

#### Composition
**Chairperson**: Hospital administrator or CMO
**Members**:
- Infection control professional
- Infectious disease physician
- Microbiologist
- Epidemiologist
- Nursing representative
- Environmental services
- Pharmacy representative

#### Responsibilities
**Policy development**:
- **Infection control policies**: Evidence-based guidelines
- **Antimicrobial stewardship**: Program development
- **Surveillance protocols**: Data collection methods

**Surveillance activities**:
- **HAI monitoring**: Prevalence and incidence
- **Outbreak investigation**: Rapid response
- **Risk assessment**: Targeted surveillance
- **Reporting**: Internal and external notification

**Education and training**:
- **Staff education**: Infection prevention
- **Orientation programs**: New employee training
- **Competency assessment**: Skills validation
- **Annual training**: Continuing education

#### Quality Improvement
**Performance monitoring**:
- **Compliance rates**: Hand hygiene, isolation precautions
- **Process indicators**: Bundle compliance
- **Outcome measures**: HAI rates, resistance

**Root cause analysis**:
- **Systems approach**: Human factors analysis
- **Process improvement**: Corrective action plans
- **Sustainability**: Long-term effectiveness

#### Regulatory Compliance
**Accreditation standards**:
- **Joint Commission**: Infection control standards
- **CMS requirements**: Medicare participation
- **State regulations**: Local health department

**Documentation**:
- **Meeting minutes**: Decisions and actions
- **Policy updates**: Revision history
- **Training records**: Staff competency
- **Incident reports**: Investigation findings

---

## CHAPTER 28: TRAVEL MEDICINE

### I. TRAVEL-RELATED DISEASES

#### Geographic Distribution
**Tropical diseases**: 
- **Sub-Saharan Africa**: Malaria, yellow fever, sleeping sickness
- **South Asia**: Malaria, dengue, chikungunya
- **Southeast Asia**: Malaria, dengue, JE, typhoid
- **South America**: Malaria, yellow fever, dengue
- **Middle East**: MERS, traveler's diarrhea

**Climate zones**:
- **Tropical (0-23.5°)**: Highest disease burden
- **Subtropical (23.5-35°)**: Seasonal transmission
- **Temperate (35-66.5°)**: Limited endemic diseases
- **Arctic/Antarctic**: Cold-related injuries

#### Traveler's Diarrhea
**Incidence**: 20-60% of international travelers
**Common pathogens**:
- **Enterotoxigenic E. coli (ETEC)**: Most common
- **Shigella, Salmonella, Campylobacter**
- **Giardia, Cryptosporidium**: Protozoal causes
- **Viruses**: Norovirus, rotavirus

**Clinical presentation**:
- **Mild**: 1-3 loose stools/day, cramping
- **Moderate**: 4-5 stools/day, fever, blood
- **Severe**: >6 stools/day, dehydration

**Treatment**:
- **Mild**: Symptomatic, loperamide
- **Moderate**: Antibiotics (ciprofloxacin, azithromycin)
- **Severe**: Aggressive fluid replacement, hospitalization

#### Vector-Borne Diseases
**Malaria**:
- **Chemoprophylaxis**: Based on resistance patterns
- **Personal protection**: Repellents, nets, clothing
- **Geographic risk**: WHO malaria maps

**Yellow fever**:
- **Endemic areas**: Tropical Africa, South America
- **Vaccination**: International certificate required
- **Complications**: Hemorrhagic fever, hepatitis

**Dengue fever**:
- **Urban transmission**: *Aedes aegypti*
- **No chemoprophylaxis**: Prevention only
- **Clinical severity**: Secondary infection risk

### II. VACCINATION REQUIREMENTS

#### Routine Vaccinations
**Adult vaccination update**:
- **Tdap**: Tetanus, diphtheria, pertussis booster
- **MMR**: Measles, mumps, rubella (if non-immune)
- **Varicella**: Chickenpox (if no history)
- **Influenza**: Annual vaccination
- **Pneumococcal**: Age >65 years

**Travel-specific vaccines**:
- **Hepatitis A**: Endemic areas
- **Typhoid**: South Asia, developing countries
- **Meningococcal**: Hajj pilgrimage, Sub-Saharan Africa

#### Routine Vaccinations for Travelers
**Hepatitis A**:
- **Schedule**: 0, 6-12 months (Havrix)
- **Single dose**: Short-term protection (1 year)
- **Duration**: Long-term after 2 doses

**Typhoid**:
- **Injectable**: Vi polysaccharide vaccine (single dose)
- **Oral**: Live attenuated (4 doses, 2-day interval)
- **Duration**: 2-3 years protection

**Japanese Encephalitis**:
- **Inactivated**: 3-dose schedule (0, 7, 30 days)
- **Duration**: 2-3 years protection
- **Indicators**: Rural travel, long stay

#### Yellow Fever Vaccination
**Indications**:
- **Endemic areas**: WHO endemic zones
- **Entry requirements**: Some countries require proof
- **High-risk activities**: Rural travel, game parks

**Certificate**:
- **Validity**: 10 days after vaccination
- **International certificate**: WHO approved center
- **Medical exemption**: Contraindications

#### COVID-19 Considerations
**Vaccination status**:
- **WHO-approved vaccines**: International recognition
- **Booster recommendations**: Based on time since vaccination
- **Entry requirements**: Country-specific policies

### III. MALARIA PROPHYLAXIS

#### Risk Assessment
**Geographic risk**:
- **WHO malaria maps**: Transmission intensity
- **Drug resistance**: Chloroquine, mefloquine resistance
- **Seasonal variation**: Peak transmission periods

**Individual factors**:
- **Age**: Pregnancy, children <5 years
- **Medical conditions**: Immunosuppression, G6PD deficiency
- **Travel itinerary**: Rural vs urban, duration

#### Prophylactic Regimens

**Chloroquine**:
- **Indications**: Sensitive areas (Central America, Caribbean)
- **Dose**: 500mg weekly, 2 weeks before travel
- **Duration**: 4 weeks after departure

**Mefloquine**:
- **Indications**: Resistant areas
- **Dose**: 250mg weekly, 2 weeks before travel
- **Duration**: 4 weeks after departure
- **Side effects**: Neuropsychiatric reactions

**Doxycycline**:
- **Indications**: Multi-drug resistant areas
- **Dose**: 100mg daily, 1-2 days before travel
- **Duration**: 4 weeks after departure
- **Side effects**: Photosensitivity, esophagitis

**Atovaquone/proguanil (Malarone)**:
- **Indications**: Multi-drug resistant areas
- **Dose**: 250/100mg daily, 1-2 days before travel
- **Duration**: 1 week after departure
- **Advantages**: Short post-travel period, fewer side effects

#### Special Populations
**Pregnant women**:
- **Chloroquine + proguanil**: Limited resistance
- **Avoid**: Mefloquine (second trimester)
- **Contraindicated**: Doxycycline, atovaquone/proguanil

**Children**:
- **Weight-based dosing**: Age-appropriate formulations
- **Avoid**: Doxycycline <8 years
- **Malarone**: >11 kg body weight

**Immunosuppressed**:
- **Expert consultation**: ID physician guidance
- **Adherence**: Importance of consistent use
- **Return monitoring**: Symptom awareness

### IV. TRAVELER'S HEALTH ADVICE

#### Pre-Travel Preparation
**Health assessment**:
- **Medical evaluation**: Chronic conditions, medications
- **Vaccination status**: Routine and travel vaccines
- **Destination research**: Health risks, medical facilities
- **Insurance**: Travel health, evacuation coverage

**Medical kit**:
- **Prescription medications**: Adequate supply, documentation
- **Over-the-counter drugs**: Pain relievers, antidiarrheals
- **First aid supplies**: Bandages, antiseptic
- **Travel-specific**: Malaria prophylaxis, altitude sickness

#### During Travel
**Food and water safety**:
- **Safe foods**: Cooked, peeled, peeled-by-you
- **Water purification**: Boiling, filtration, chemical treatment
- **Street food**: Avoid or ensure proper preparation
- **Ice**: Avoid unless made from safe water

**Personal protection**:
- **Insect repellents**: DEET 20-30%, picaridin
- **Protective clothing**: Long sleeves, pants, closed shoes
- **Bed nets**: insecticide-treated nets
- **Accommodation**: Air conditioning, window screens

**Activity-specific advice**:
- **Swimming**: Freshwater precautions (schistosomiasis)
- **Animal contact**: Rabies risk, petting zoos
- **Altitude**: Gradual ascent, acetazolamide
- **Adventure activities**: Travel insurance, safety equipment

#### Post-Travel Health
**Illness evaluation**:
- **Fever**: Malaria consideration, seek immediate care
- **Diarrhea**: Persistent symptoms, evaluation needed
- **Skin conditions**: Insect bites, fungal infections
- **Respiratory**: Tuberculosis consideration

**Follow-up care**:
- **Routine check-up**: 4-6 weeks post-travel
- **Malaria monitoring**: Symptoms up to 1 year
- **Vaccination completion**: Hepatitis A, typhoid series
- **TB screening**: High-risk exposure, latent infection

### V. INTERNATIONAL HEALTH REGULATIONS

#### WHO International Health Regulations (IHR 2005)
**Core capacities**:
- **Surveillance**: Disease detection and reporting
- **Response**: Emergency preparedness and response
- **Communication**: Information sharing between countries
- **Health measures**: Border health controls

#### Reporting Requirements
**Notifiable diseases**:
- **Smallpox**: Any case
- **Poliomyelitis**: Acute flaccid paralysis
- **SARS**: Severe acute respiratory syndrome
- **Influenza**: Novel subtypes

**Public health emergency of international concern (PHEIC)**:
- **Declaration criteria**: Serious, unusual, unexpected
- **PHEIC examples**: H1N1 (2009), Ebola (2014-2016), Zika (2016), COVID-19 (2020)

#### Travel Documentation
**International Certificate of Vaccination**:
- **Yellow fever**: Only vaccine requiring certificate
- **Format**: Standard WHO certificate
- **Validity**: 10 days after vaccination
- **Medical contraindication**: Temporary exemption

**Health declarations**:
- **Arrival screening**: Temperature, symptom assessment
- **Contact tracing**: Passenger information systems
- **Quarantine measures**: Isolation for exposed persons

#### Border Health Measures
**Departure screening**:
- **Exit screening**: Fever, symptoms assessment
- **Health notices**: Travel advisories
- **Vaccination proof**: Yellow fever certificate

**Arrival screening**:
- **Entry screening**: Temperature checks, health declarations
- **Risk assessment**: Travel history, vaccination status
- **Contact information**: Passenger locator forms

---

## EXAMINATION POINTS - KEY MEMORY AIDS

### Transmission Patterns
**Respiratory**: Cough, sneeze, speak, sing
**Fecal-oral**: "5 Fs" - Food, Fingers, Flies, Feces, Fluids
**Vector-borne**: Mosquito bite at dusk/dawn
**Sexual**: Unsafe sex, multiple partners
**Bloodborne**: Needles, transfusions, organ transplants

### Drug-Resistance Mnemonics
**MRSA**: Methicillin-Resistant *Staphylococcus aureus*
**ESBL**: Extended-Spectrum Beta-Lactamases
**CRE**: Carbapenem-Resistant Enterobacterales
**XDR-TB**: Extensively Drug-Resistant Tuberculosis

### National Programme Abbreviations
**RNTCP**: Revised National Tuberculosis Control Programme
**NLEP**: National Leprosy Elimination Programme
**NACP**: National AIDS Control Programme
**NMCP**: National Malaria Control Programme
**NVBDCP**: National Vector Borne Disease Control Programme

### Diagnostic Tests
**TB**: "Z-N stain + GeneXpert"
**HIV**: "ELISA + Western Blot confirmation"
**Malaria**: "RDT + microscopy"
**Dengue**: "NS1 early + IgM late"
**Typhoid**: "Widal + blood culture"

### Treatment Regimens
**TB**: "2HRZE/4HR" (2 months intensive, 4 months continuation)
**Malaria**: "ACT for falciparum" (Artemisinin Combination Therapy)
**Leprosy**: "MDT for MB/PB" (Multidrug Therapy)
**STIs**: "Ceftriaxone + Azithromycin" for gonorrhea

---

*End of Part VI: Communicable Diseases*